Sentences with phrase «studied as a cancer therapy»

The active ingredient in them, amygdalin, also called laetrile and «vitamin B 17» has been studied as a cancer therapy.

Not exact matches

The process of integrating naturally occurring cancers in dogs into the general studies of human cancer biology and therapy is known as comparative oncology.

Tissue engineering provides a more practical means for researchers to study cell behavior, such as cancer cell resistance to therapy, and test new drugs or combinations of drugs to treat many diseases.

Hormone replacement therapy has been controversial over the past few decades as studies have associated it with both health benefits — lowering the risk of osteoporosis and improving some measures of heart health, for example — and risks, including links to cancer and stroke.

«It is expected that this study will lay the foundation for developing a new class of potent and effective cancer therapies and the development of reagents targeting epigenetic events in immune - mediated diseases as well as other epigenetically - influenced diseases,» said Alani, who also is chief of dermatology at Boston Medical Center.

«This study opens the door for combination therapy with BRAF inhibitors and autophagy inhibitors, which haven't been explored deeply as a therapeutic option for patients whose tumors are resistant,» said Ravi K. Amaravadi, MD, assistant professor of Medicine in the division of Hematology / Oncology at the Perelman School of Medicine and co-leader of the Cancer Therapeutics Program at Penn Medicine's Abramson Cancer Center.

During her final two years at the agency, she had directed the Lab of Antiviral Drug Mechanisms, where she studied therapies for AIDS as well as one of its associated cancers, Kaposi's sarcoma.

«As these drugs are considerably cheaper than current therapies, they can improve treatment in the developing world where the number of deaths from cancer is predicted to increase significantly over the next ten years,» said Dr Federica Sotgia, another leader of the study.

«These findings will give women with early stage breast cancer greater certainty that anti-estrogen therapy will decrease their risk of recurrence and increase their chance for survival whereas chemotherapy will not,» said breast cancer survivor Mary Lou Smith, JD, MBA, who helped design the study as a leader in the ECOG - ACRIN Cancer Research Advocates Commcancer greater certainty that anti-estrogen therapy will decrease their risk of recurrence and increase their chance for survival whereas chemotherapy will not,» said breast cancer survivor Mary Lou Smith, JD, MBA, who helped design the study as a leader in the ECOG - ACRIN Cancer Research Advocates Commcancer survivor Mary Lou Smith, JD, MBA, who helped design the study as a leader in the ECOG - ACRIN Cancer Research Advocates CommCancer Research Advocates Committee.

Importantly this article suggests that geranylgeraniol deserves further study as a potential therapy for human prostate cancer.»

In 2003, breast cancer rates dropped rapidly, and several studies in 2007 cited decreased use of hormone replacement therapy (HRT) as the likely cause.

Because those organoids include stroma, a scaffold of connective tissue essential for tumor growth, they may prove better for studying therapies that target the stroma, such as cancer immunotherapy.

Our study opens the possibility of modulating KSR as a new cancer therapy and also potentially an entirely new class of interventions.»

In a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutacancer patients with B - raf mutations.

As part of a second trial, Swanton's lab will also study what happens to tumors under the selective pressure of various types of cancer therapies, from traditional chemotherapy to targeted drugs.

Genetically modified «hunter» T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat this aggressive cancer, Penn Medicine researchers report in a new study this week in Science Translational Medicine.

As recent data suggest, PSMA is an important cancer antigen expressed on many human prostate, bladder, renal as well as ovarian cancers, so additional study of the possible benefits of this therapy are important.&raquAs recent data suggest, PSMA is an important cancer antigen expressed on many human prostate, bladder, renal as well as ovarian cancers, so additional study of the possible benefits of this therapy are important.&raquas well as ovarian cancers, so additional study of the possible benefits of this therapy are important.&raquas ovarian cancers, so additional study of the possible benefits of this therapy are important.»

This is the first population - based study to compare the follow - up intensity of American men with prostate cancer who have not undergone aggressive treatment with those who opted to undergo various forms of aggressive therapy, such as surgery and radiation.

«In its original review of these studies, the UK Gene Therapy Advisory Committee recognised the possibility of cancer occurring as a result of this type of gene therapy,» says Norman Nevin, GTAC's chTherapy Advisory Committee recognised the possibility of cancer occurring as a result of this type of gene therapy,» says Norman Nevin, GTAC's chtherapy,» says Norman Nevin, GTAC's chairman.

New studies from the Abramson Cancer Center of the University of Pennsylvania are providing fresh clues on potentially effective combinations with CAR T therapy in brain cancer as well as a novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic cCancer Center of the University of Pennsylvania are providing fresh clues on potentially effective combinations with CAR T therapy in brain cancer as well as a novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic ccancer as well as a novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic ccancer, and also providing greater understanding of the mechanisms of resistance in pancreatic cancercancer.

Now a new study from the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1 - 2 deficient ovarian cancer is likely to respond to checkpoint inhibitor thCancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1 - 2 deficient ovarian cancer is likely to respond to checkpoint inhibitor thcancer is likely to respond to checkpoint inhibitor therapy.

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

Hence, scientists have begun studying BRCA - targeted gene therapy as an effective treatment for breast cancer.

Due to the high efficiency of establishing organoid models from different tissues and diseases, such as cancer, organoid technology allows the generation of large living biobanks of tumor organoids that are amenable for middle - throughput drug screens and may allow personalized therapy design, as a complement to cell line and xenograft - based drug studies (7,19).

«Dr. Meyers» research is a perfect example as to how fundamental laboratory studies are leading to innovative and novel therapies for breast cancer treatment,» says Dr. Raymond Hohl, director of the Penn State Hershey Cancer Instcancer treatment,» says Dr. Raymond Hohl, director of the Penn State Hershey Cancer InstCancer Institute.

But if, as this study suggests, the way that cells become proliferative again is similar across many different organs, we can imagine therapies that interfere with cancer initiation in a more global way, regardless of where that cancer may appear in the body,» he explains.

The study highlights an opportunity to combine this form of therapy with cancer immunotherapy drugs such as checkpoint inhibitors, which unleash the immune system's full cancer - fighting power, the researchers say.

The cellular processes that we have identified in this study as being important for the development of stomach cancer provide new targets for therapy that have not been explored before,» Dr. O'Reilly said.

As a member of the Vaccine & Immunotherapy Center he studied accelerated vaccine development and targeted cancer therapies until February 2015.

«The goals of maintenance therapy, as are the goals of all treatment in patients with advanced NSCLC, and perhaps all advanced cancers, is to prolong survival, and to improve or maintain quality of life,» said Gregory Kalemkerian, of the University of Michigan; he was not involved with the study.

Potential cardioprotection was based on generally supportive data on lipid levels in intermediate outcome clinical trials, trials in nonhuman primates, and a large body of observational studies suggesting a 40 % to 50 % reduction in risk among users of either estrogen alone or, less frequently, combined estrogen and progestin.2 - 5 Hip fracture was designated as a secondary outcome, supported by observational data as well as clinical trials showing benefit for bone mineral density.6, 7 Invasive breast cancer was designated as a primary adverse outcome based on observational data.3, 8 Additional clinical outcomes chosen as secondary outcomes that may plausibly be affected by hormone therapy include other cardiovascular diseases; endometrial, colorectal, and other cancers; and other fractures.3, 6,9

The study provides a new path forward in human research as about half of the breast cancers treated with this common cancer therapy do not respond well, say researchers at the Georgetown Lombardi Comprehensive Cancer Center, who led the multi-institutional rescancer therapy do not respond well, say researchers at the Georgetown Lombardi Comprehensive Cancer Center, who led the multi-institutional resCancer Center, who led the multi-institutional research.

Dr. Tran also received a $ 1 million Movember - Prostate Cancer Foundation Challenge Award to study the stereotactic radiation therapy as an immune stimulating approach to advanced prostate cCancer Foundation Challenge Award to study the stereotactic radiation therapy as an immune stimulating approach to advanced prostate cancercancer.

These studies support the idea that nutrient transporters can be exploited as potential drug targets for cancer therapy and usher us into a new era of novel cancer therapeutics beyond kinase inhibitors and growth factor receptor blockers.

Important reports from the Weiner lab include the first DNA vaccine studied for HIV as well as for cancer immune therapy of cutaneous T cell lymphoma, the early development of DNA encoded genetic adjuvants, including IL - 12, advances in gene optimization, and advances in electroporation technologies resulting in improved gene delivery.

Fueled by a recent resurgence in public financing and compelling clinical data for indications as diverse as acute macular degeneration and pancreatic cancer, a growing number of cell therapies are driving toward pivotal clinical studies and commercialization.

By studying them, we are beginning to gain insight into human disease — to understand why organs such as the heart can not repair themselves or why, as we age, the incidence of debilitating diseases such as cancer, heart disease and Alzheimer's increases so rapidly, and we are developing new therapies that will enhance our abilities to regenerate damaged tissues and prolong healthy lifespan.

Johns Hopkins researchers then study stem cell infusion as therapy for cancer treatment toxicity, diabetes, cystic fibrosis, and other diseases.

An authority on the study and treatment of childhood cancers, as well as the biology and therapy of hemoglobinopathies — blood diseases such as sickle cell anemia and thalassemia — Cunningham is known for his work on understanding the molecular mechanism underpinning red blood cell production.

«If the pilot trial is successful, we plan to pursue a larger trial to explore this strategy's potential as a straightforward and cost - effective way to improve the existing therapy for AML and MDS,» said Peter Jones, Ph.D., D.Sc., co-senior author of the PNAS study, chief scientific officer at Van Andel Research Institute (VARI) and co-leader of the Van Andel Research Institute — Stand Up To Cancer (VARI — SU2C) Epigenetics Dream Team.

GSK3β, the first neighbour of β - catenin is a central, highly multi-functional protein known as a key protein difficult to inhibit without causing side effects and toxicity.41 In glioblastoma and NSCLC cancer, previous studies found that the decreased level of FRAT1 influences the GSK3β activity to phosphorylate β - catenin and by that, inhibit the WNT pathway.39, 40 The role of FRAT1 in colon cancer is less known but based on its function in other cancer types and its special influencing position in colon cancer signalling, we point out its relevance as a potential target in colon cancer therapy (Fig. 3d).

A second phase 3 study presented Sunday found that adding radiation to hormone therapy, also known as androgen - deprivation therapy (ADT) in patients with locally advanced or high - risk prostate cancer reduced the seven - year risk of dying by 43 percent compared to treating with hormone therapy alone.

A 2015 article in the International Journal of Biochemistry and Cell Biology sums up the findings of multiple studies on ketogenic diets and cancer with the following: «there is increasing evidence that the ketogenic diet may also be beneficial as an adjuvant cancer therapy by potentiating the antitumor effect of chemotherapy and radiation treatment.»

Studies have discovered that when the FWGE (Fermented Wheat Germ Extract) product Avemar was used as an adjunct to conventional cancer therapies, it was able to enhance the effects of those treatments while at the same time lessening their side effects.

Although these studies are relatively new, scientists believe that Borage shows great promise as an alternative cancer therapy.

Many studies have shown that at high doses, vitamin C is toxic to cancer cells, able to work synergistically with conventional therapies such as chemotherapy and radiation.

Nutritional ketosis has received a lot of attention by cancer researchers in recent years, and many studies show it has great potential not just as a form of cancer prevention but also treatment — in combination with other treatments such as chemotherapy and radiation.16 Research is looking at whether non-toxic metabolic therapies and drug cocktails may be just as effective, with less toxicity.

As part of Breast Cancer Awareness month, Roper Physical Therapy wanted to highlight a study that examined the benefits of yoga for breast cancer patCancer Awareness month, Roper Physical Therapy wanted to highlight a study that examined the benefits of yoga for breast cancer patcancer patients.

I am very encouraged by this recent study, published in January 2014, looking at the ketogenic diet and intermittent fasting as an adjunct nutritional therapy to be administered to cancer patients undergoing standard radiation therapy in cancer treatment.

Eugene Fine was also there with a poster on his just published pilot study on ketogenic diets and cancer — «Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients.»